Biolargo, Inc. – ‘10-Q’ for 6/30/22 – ‘ZIP’

On:  Monday, 8/15/22, at 5:29pm ET   ·   For:  6/30/22   ·   Accession #:  1437749-22-20577   ·   File #:  0-19709

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    937K 
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     21K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     21K 
 9: EX-32       Certification -- §906 - SOA'02                      HTML     20K 
10: R1          Document And Entity Information                     HTML     69K 
11: R2          Consolidated Balance Sheets (Current Period         HTML    158K 
                Unaudited)                                                       
12: R3          Consolidated Balance Sheets (Current Period         HTML     32K 
                Unaudited) (Parentheticals)                                      
13: R4          Consolidated Statements of Operations and           HTML    111K 
                Comprehensive Loss (Unaudited)                                   
14: R5          Consolidated Statements of Stockholders' Equity     HTML    120K 
                (Deficit) (Unaudited)                                            
15: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML    116K 
16: R7          Note 1 - Business and Organization                  HTML     28K 
17: R8          Note 2 - Summary of Significant Accounting          HTML    113K 
                Policies                                                         
18: R9          Note 3 - Sale of Stock for Cash                     HTML     23K 
19: R10         Note 4 - Debt Obligations                           HTML     41K 
20: R11         Note 5 - Share-based Compensation                   HTML    124K 
21: R12         Note 6 - Warrants                                   HTML     49K 
22: R13         Note 7 - Accounts Payable and Accrued Expenses      HTML     27K 
23: R14         Note 8 - Noncontrolling Interest - Clyra Medical    HTML     43K 
24: R15         Note 9 - Business Segment Information               HTML    113K 
25: R16         Note 10 - Commitments and Contingencies             HTML     22K 
26: R17         Note 11 - Subsequent Events                         HTML     22K 
27: R18         Significant Accounting Policies (Policies)          HTML    157K 
28: R19         Note 2 - Summary of Significant Accounting          HTML     71K 
                Policies (Tables)                                                
29: R20         Note 4 - Debt Obligations (Tables)                  HTML     33K 
30: R21         Note 5 - Share-based Compensation (Tables)          HTML    107K 
31: R22         Note 6 - Warrants (Tables)                          HTML     47K 
32: R23         Note 7 - Accounts Payable and Accrued Expenses      HTML     26K 
                (Tables)                                                         
33: R24         Note 8 - Noncontrolling Interest - Clyra Medical    HTML     43K 
                (Tables)                                                         
34: R25         Note 9 - Business Segment Information (Tables)      HTML    105K 
35: R26         Note 1 - Business and Organization (Details         HTML     49K 
                Textual)                                                         
36: R27         Note 2 - Summary of Significant Accounting          HTML     79K 
                Policies (Details Textual)                                       
37: R28         Note 2 - Summary of Significant Accounting          HTML     23K 
                Policies - Summary of Cash Balances (Details)                    
38: R29         Note 2 - Summary of Significant Accounting          HTML     40K 
                Policies - Credit Concentration (Details)                        
39: R30         Note 2 - Summary of Significant Accounting          HTML     24K 
                Policies - Inventory (Details)                                   
40: R31         Note 2 - Summary of Significant Accounting          HTML     31K 
                Policies - Stock Options, Valuation Assumptions                  
                (Details)                                                        
41: R32         Note 3 - Sale of Stock for Cash (Details Textual)   HTML     33K 
42: R33         Note 4 - Debt Obligations (Details Textual)         HTML     34K 
43: R34         Note 4 - Debt Obligations - Schedule of Debt        HTML     36K 
                (Details)                                                        
44: R35         Note 5 - Share-based Compensation (Details          HTML    112K 
                Textual)                                                         
45: R36         Note 5 - Share-based Compensation - Stock Options   HTML     79K 
                (Details)                                                        
46: R37         Note 6 - Warrants (Details Textual)                 HTML     33K 
47: R38         Note 6 - Warrants - Warrants Outstanding (Details)  HTML     37K 
48: R39         Note 7 - Accounts Payable and Accrued Expenses -    HTML     31K 
                Summary of Accounts Payable and Accrued Expenses                 
                (Details)                                                        
49: R40         Note 8 - Noncontrolling Interest - Clyra Medical    HTML    127K 
                (Details Textual)                                                
50: R41         Note 8 - Noncontrolling Interest - Clyra Medical    HTML     26K 
                Common and Preferred Shares Outstanding (Details)                
51: R42         Note 8 - Noncontrolling Interest - Summary of       HTML     27K 
                Accounts Payable and Accrued Expenses (Details)                  
52: R43         Note 9 - Business Segment Information (Details      HTML     19K 
                Textual)                                                         
53: R44         Note 9 - Business Segment Information - Segment     HTML     78K 
                Information (Details)                                            
54: R45         Note 10 - Commitments and Contingencies (Details    HTML     23K 
                Textual)                                                         
55: R46         Note 11 - Subsequent Events (Details Textual)       HTML     41K 
58: XML         IDEA XML File -- Filing Summary                      XML    110K 
56: XML         XBRL Instance -- blgo20220630_10q_htm                XML   2.07M 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     81K 
 3: EX-101.CAL  XBRL Calculations -- blgo-20220630_cal               XML    111K 
 4: EX-101.DEF  XBRL Definitions -- blgo-20220630_def                XML   1.14M 
 5: EX-101.LAB  XBRL Labels -- blgo-20220630_lab                     XML    901K 
 6: EX-101.PRE  XBRL Presentations -- blgo-20220630_pre              XML   1.15M 
 2: EX-101.SCH  XBRL Schema -- blgo-20220630                         XSD    167K 
59: JSON        XBRL Instance as JSON Data -- MetaLinks              323±   487K 
60: ZIP         XBRL Zipped Folder -- 0001437749-22-020577-xbrl      Zip    181K 

‘ZIP’   —   XBRL Zipped Folder — 0001437749-22-020577-xbrl

This is an XBRL Zipped Folder.

	Download this zipped .zip folder
Files:	blgo-20220630.xsd blgo-20220630_cal.xml blgo-20220630_def.xml blgo-20220630_lab.xml blgo-20220630_pre.xml blgo20220630_10q.htm ex_412281.htm ex_412282.htm ex_412283.htm

18 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/24/22  Biolargo, Inc.                    8-K:1,9     3/22/22   12:169K                                   RDG Filings/FA
 3/08/22  Biolargo, Inc.                    8-K:1,9     3/03/22   13:328K                                   RDG Filings/FA
 3/30/21  Biolargo, Inc.                    10-K       12/31/20   73:9.1M                                   RDG Filings/FA
 3/19/21  Biolargo, Inc.                    8-K:1,9     3/18/21    2:44K                                    RDG Filings/FA
 8/14/20  Biolargo, Inc.                    10-Q        6/30/20   61:7.4M                                   RDG Filings/FA
 7/07/20  Biolargo, Inc.                    8-K:1,9     6/30/20    6:191K                                   RDG Filings/FA
 3/31/20  Biolargo, Inc.                    8-K:1,9     3/30/20    3:419K                                   RDG Filings/FA
12/19/18  Biolargo, Inc.                    8-K:1,9    12/17/18    4:80K                                    RDG Filings/FA
10/02/18  Biolargo, Inc.                    8-K:1,3,5,9 9/26/18    6:355K                                   RDG Filings/FA
 6/22/18  Biolargo, Inc.                    POS AM                 3:2.8M                                   RDG Filings/FA
 6/22/18  Biolargo, Inc.                    S-8         6/22/18    8:502K                                   RDG Filings/FA
 8/24/16  Biolargo, Inc.                    8-K:1,9     8/18/16    2:9.3M                                   RDG Filings/FA
 1/06/16  Biolargo, Inc.                    8-K:3,8,9  12/30/15    7:462K                                   RDG Filings/FA
 3/31/15  Biolargo, Inc.                    10-K       12/31/14   75:15M                                    RDG Filings/FA
 5/02/11  Biolargo, Inc.                    DEF 14C     4/29/11    1:627K                                   RDG Filings/FA
11/19/07  Biolargo, Inc.                    10QSB       9/30/07    6:449K                                   Donnelley … Solutions/FA
 5/04/07  Biolargo, Inc.                    10KSB      12/31/06   19:1.4M                                   Donnelley … Solutions/FA
 5/23/03  Biolargo, Inc.                    10KSB      12/31/02   15:591K                                   Toppan Merrill/FA